



Gordon Kit  
T 202-663-7945  
gkit@sughrue.com

July 23, 2001

BOX PCT  
Commissioner for Patents  
Washington, D.C. 20231

PCT/ES00/00026-filed  
January 21, 2000

Re: Application of Eliseo Quintanilla ALMAGRO  
and Joaquín DIAZ ALPERI entitled  
"A PHARMACEUTICAL COMPOSITION CAPABLE  
OF REGULATING THE EXPRESSION OF ADHESION  
MOLECULES"  
**ESPECIALIDADES FARMACEUTICAS CENTRUM, S.A.**  
Our Ref: Q-65077

Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. § 371 and in accordance with Chapter II of the Patent Cooperation Treaty:

- the International Application, along with an English translation thereof.
- an International Preliminary Examination Report.
- a Preliminary Amendment.

The executed Declaration and Power of Attorney and Assignment will be submitted at a later date.

It is assumed that copies of the International Application and the International Preliminary Examination Report as required by § 371(c) will be supplied directly by the International Bureau. However, for the Examiner's convenience, a copy of each of which is provided herewith.

Priority is claimed from January 25, 1999, based on Spanish Application No. 9900182.

09/889846 09/889846  
JC18 Rec'd PCT/PTO 23 JUL 2001

SUGHRUE MION ZINN MACPEAK & SEAS, PLLC

Commissioner for Patents

July 23, 2001  
Page 2

The Government filing fee is calculated as follows:

TOTAL FEE \$1160.00

A check for the statutory filing fee, in the amount of \$1,160.00, is submitted herewith.

However, the Commissioner is hereby directed and authorized to charge or credit any difference or overpayment to Deposit Account No. 19-4880. The Commissioner is also hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.492 which may be required during the entire pendency of the application to Deposit Account No. 19-4880. A duplicate copy of this transmittal letter is attached.

~~Respectfully submitted,~~

Gordon Kit  
Registration No. 30,764

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eliseo Quintanilla ALMAGRO et al

CHAPTER II filing  
Appln. No.: of PCT/ES00/00026 Group Art Unit: 0000

Filed: July 23, 2001 Examiner: Unknown

For: A PHARMACEUTICAL COMPOSITION CAPABLE OF REGULATING  
THE EXPRESSION OF ADHESION MOLECULES

PRELIMINARY AMENDMENT

Assistant Commissioner  
of Patents  
Washington, D.C. 20231

Sir:

Prior to examining the above-identified application, please amend the application as follows.

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 1, before line 3, insert

--- This application is a 371 of PCT/ES00/00026, filed January 21, 2000. --.

IN THE CLAIMS:

Please cancel Claims 1-7 in their entirety.

Please add the following new claims:

-- Claim 8. (New) A method for inhibiting expression of an adhesion molecule comprising administering, to a subject in need thereof, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of

PRELIMINARY AMENDMENT  
CHAPTER II filing of PCT/ES00/00026

*Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

Claim 9. (New) The method of Claim 8, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction.

Claim 10. (New) The method of Claim 8, wherein said adhesion molecule is the alpha chain of integrin  $\beta$ -2, the beta chain of integrin  $\beta$ -2, or both.

Claim 11. (New) The method of Claim 8, wherein said adhesion molecule is CD54.

Claim 12. (New) The method of Claim 8, wherein said adhesion molecule is CD11b, CD6L or a combination thereof.

Claim 13. (New) A method for inhibiting inflammation comprising administering, to a subject in need thereof, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of *Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

Claim 14. (New) The method of Claim 13, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction.

Claim 15. (New) A method for immuno-modulation comprising administering, to a subject in need thereof, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of *Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

**PRELIMINARY AMENDMENT**  
**CHAPTER II filing of PCT/ES00/00026**

Claim 16. (New) The method of Claim 15, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction.

Claim 17. (New) A method for normalization of C4+CD29+CD45RA+ lymphocyte populations comprising administering, to a subject afflicted with a disease wherein said populations are increased, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of *Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

Claim 18. (New) The method of Claim 17, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction.

Claim 19. (New) A method for treatment of multiple sclerosis comprising administering, to a subject afflicted with multiple sclerosis, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of *Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

Claim 20. (New) The method of Claim 19, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction. --

**REMARKS**

The specification has been amended to insert formal matter; Claims 1-7 have been deleted and new Claims 8-20 added in order to remove improper dependency and make the application consistent with U.S. patent practice.

**PRELIMINARY AMENDMENT**  
**CHAPTER II filing of PCT/ES00/00026**

In view of the amendment to the specification, the cancellation of Claims 1-7 and the addition of new Claims 8-20, allowance is respectfully requested.

The Examiner is invited to contact the undersigned at his Washington telephone number on any questions which might arise.

Respectfully submitted,



Gordon Kit

Registration No. 30,764

**SUGHRUE, MION, ZINN,  
MACPEAK & SEAS, PLLC**  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3202  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: July 23, 2001

A P P E N D I X

Marked-up Version of Changes

IN THE SPECIFICATION:

The specification is amended as follows:

Page 1, before line 3,

--- This application is a 371 of PCT/ES00/00026, filed January 21, 2000. ---.

IN THE CLAIMS:

The claims are changed as follows:

Claims 1-7 are cancelled.

New Claims 8-20 are added.

A PHARMACEUTICAL COMPOSITION CAPABLE OF REGULATING THE  
EXPRESSION OF ADHESION MOLECULES.

**FIELD OF THE INVENTION**

The present invention relates to a novel pharmacological 5 use of Anapsos. Anapsos is a neutral extract of *Polypodium* comprising 118 milligrams of a water soluble extracts and 2 milligrams of a lipid soluble fraction.

The present invention describes the involvement of the 10 Anapsos in the regulation of the expression of the adhesion molecules. Anapsos reduces the expression of the alpha chain of integrins  $\beta$ -2 (CD11a and CD11b), the beta chain of integrins  $\beta$ -2 (CD18), and the differentiation antigen CD54 of the immunoglobulins superfamily. It is 15 also capable of normalizing alterations of the immunological phenotype.

Further, is described the use of Anapsos in any diseases 20 where an excess of inflammation, derived from cellular and tissue lesions, is responsible for pathologically symptoms and indications.

**BACKGROUND OF THE INVENTION**

The cells of the immune system are in contact with other 25 cells and the extra-cellular matrix in order to efficiently perform their required functions. This is due to that they must be able to recognize the situation of their surroundings. Accordingly, the leukocytes not only have specific surface receptors capable of being specifically activated in response to determined stimuli, but 30 also comprises a number of molecules which globally are called adhesion molecules. The adhesion molecules act as

receptors for ligands which are situated on other cells and as receptors capable of binding amino acid sequences present in different extracellular matrix proteins, such as collagen, fibronectin, lamina, and others. The adhesion molecules, beside being involved in the cell - cell and cell - extracellular matrix adhesion, collaborate in the cellular activation by sending co-activator signals into the interior of the cell.

The migration of leukocytes to the tissue, essential for the immunological response, is mediated by a number of molecular interactions where the adhesion molecules play a fundamental role. The adhesion molecules are classified into 3 structural based categories:

- the selectins
- the family of integrins
- the superfamily of immunoglobulins

In the first step of inflammation, the leukocytes accumulate around the endothelial wall causing the endothelial cells to remove themselves from each other. This initial process is mediated by the interaction of specific endothelial selectins (selectin E and P) and their corresponding leukocyte receptor (sLex) and between leukocyte selectin L and specific adhesion molecules of the endothelium. Simultaneously, with the expression of the adhesion molecules, are also released pro-inflammatory cytokines. Following, an activation signal induces a conformational change in the extra-cellular domains of the leukocyte integrins which gives a stronger adhesion. This is mediated by interactions between specific integrins and their ligands (LFA-1/ICAM-1, VLA-4/VCAM-1). As a consequence of the leukocyte/endothelium adhesion the accumu-

lation of leukocytes is reduced and there are produced extravasation and migration of the leukocytes, from the blood circulation to the focus of inflammation, by chemotaxis. Consequently, the adhesion molecules are responsible for different processes of adhesion, mediating the final adhesion to the endothelium, the extravasation, and the migration towards the focus of inflammation.

The alpha and beta chains of the integrins  $\beta$ -2 (CD11a, CD11b, CD18) are extended throughout all tissues. Consequently, a decrease in their expression gives an anti-inflammatory effect in the tissues. The adhesion molecule CD54 belongs to the immunoglobulin superfamily and is also highly distributed in various tissues, such as endothelium, leukocytes, etc.

In patients with multiple sclerosis there has been observed an increase in the lymphocytic population CD4+CD29+CD45RA. Further, recent data from the literature of virgin and memory cells indicates that revertant CD4+CD29+CD45RA+ cells are of fundamental importance as these are the authentic memory cells. They have a longer half-life as compared to CD45RO+ and once activated capable of being maintained years in the organism.

25

Inflammation, which might well be a normal physiological process, is when it is taken to its extreme converted into a pathological issue. For example, this happens in the major part of the auto-immune processes (systematic or organ specific), chronic inflammatory diseases, or infections which symptoms are characterized by an exaggerated inflammation giving rise to the corresponding damage

of organs or tissues. Consequently, any medicament capable of decreasing the expression of the adhesion molecules, which under inflammation processes normally have an increased expression, may be suitable for the treatment 5 of these diseases, independently of the aetiological cause of the specific disease. Such disease might be neuro-degenerative disorders (multiple sclerosis, Alzheimer), and connective tissue diseases (systemic lupus eritematose, Sjögren syndrome, reumatoide arthritis, 10 Behçet disease, etc).

The anti-inflammatory action, due to reduction of the expression of the adhesion molecules, is performed independently of the inhibition-stimulation of the inflammatory cytokines and the stimulatory effect of the cellular immunity (increase of TH1-like cytokines and increase of T CD8+ lymphocytes and NK cells). 15

The extracts of the genus of the *Polypodiaceae* family 20 have traditionally been used in Central America in the popular medicine attributing to it different activities such as: anti-inflammatory activity, *Boletín de la Sociedad Química del Perú* pag 91 (1988); prevention of tumor malignant, *Nature* 214: 1256-1258 (1967). There have 25 been described clinical effects in diseases related to immunological deficits, such as atopic dermatitis; *Dermatología* 173: 154-156 (1986); atopic dermatitis, *Allergology et Immunopathology* 15: 185-189 (1987); *International Journal of Dermatology* 13: 276-282 (1974); *Planta 30 Médica* 58: 306-310 (1992) and vitiligo, *International journal of Dermatology* 28: 479 (1989). In these publications it has been identified that the extracts of *Polyptodium leucotomos* have activity in relation to hyperquer-

tosis, paraquerotosis, epidermal mitosis, and lesions of the epidermis.

The extracts of these ferns have been described to have  
5 immuno-modulatory capacity in patients with atopic dermatitis, giving a normalization of the CD4+/CD8+ relation after treatment with extract of *Polypodium leucotomos* (Anapsos®), **Dermatológica 173:154-56 (1986)**; **Annals Immunologie 134:393-400 (1983)**. **Annals of Psychiatry 3: 329-341 (1992)** describes that the Anapsos® improve the memorizing, decrease the levels of cytokines IL-1 $\beta$ -2 and IL-2 in the frontparietal cortex and decrease IL-1 $\beta$  in hippocampus, **Br. J. Clin. Pharmacol 43: 85-89 (1997)** describes the immuno-modulatory effect in vitro of the polar extract of *Polypodium leucotomos* (Anapsos®) in relation to the cytokines IL-1 $\beta$ , IL-2, IL-10, INF- $\gamma$  which could give a pleiotropic effect in the different populations of the immune system.

20 Concerning the patent literature following documents of relevance have been identified.

The European patent application **EP-503.208** describes a process for obtaining a water-soluble extract by extraction of the leaves and/or rhizomes of different ferns. This document specifies that these extracts have immunological activity and consequently useable in diseases involving a depression of the immune system, generally with a deficit of T suppressor lymphocytes, and with beneficial effects in the auto-immune diseases and viral infections. Examples of pathological utilities are: reumatoide arthritis, lupus eritematoso, syndrome of Sjögren, multi-

ple sclerosis, hepatitis B, syndrome of Di George, auto-haemolytic anaemia, atopic dermatitis, psoriasis, Basedow disease, Chron disease, mistenia, vitiligo, herpes zoster, etc. The extract increases the level of T-suppressor 5 lymphocytes.

The Spanish patent **ES-2.088.770** teaches a pharmaceutical composition based on a water-soluble and a lipid soluble fraction of the leaves and/or rhizomes of different ferns 10 with beneficial effects against cognitive dysfunctions, and/or neuroimmunes, in particular for the treatment of Alzheimer disease.

The patent **US-5.614.197** describes the use of extracts of 15 *Polypodium* as photo-protector agents and as anti-oxidants. The Spanish patent **ES-470.204** relates to natural terpenes with anti-psoriasis activity which are obtained by extraction of the rhizomes and leaves of different ferns. The Spanish patent **ES-490.293** relates to a 20 medicament with anti-inflammatory effects in pathological problems which affects the osteolocomotor apparatus of the human organism, specially the arthritis. The medicament is obtained as extracts from fern of the family *Polypodiaceae* using both the leaves and the rhizomes. The 25 patent **US-3.839.553** uses the extracts of *Polypodium* as capillary conditioners. The French patent **FR-2.395.266** relates to obtaining a  $\alpha$ -d-gluco-octane-delta-1-lactone-eno-diol and its calcium salt starting from the ferns of *Polypodium*, having immuno-suppressing and antiviral activity 30 in mammals.

The patent application having the publication number WO-97/40838 describes the use of a sulfur lipid for the treatment of inflammatory disorders of the skin, specially in psoriasis, by inhibition of the plaque aggregation factor. The sulfur lipid is obtained from leaves by methanol extraction.

The Polypodium extracts as described in the art are water-soluble or hydrophilic extracts which may be obtained by extraction with polar solvents followed by different purification steps such as purification by resins via inter-chancing of ions, absorption over active carbon followed by evaporation of the solvents or lyophilization. Corresponding, the lipid or lipid soluble fractions may be obtained by extraction with apolar solvents such as hexane, chloroform, or ether to obtain the different triterpenes present in the leaves and/or rhizomes. The pharmaceutical composition of the present invention comprises as active ingredient the extract of Polypodium, Anapsos, corresponding to the pharmaceutical composition as described in the Spanish patent ES-2.088.770. It comprises a water-soluble and a lipid soluble fraction and pharmaceutically acceptable carriers. Each unit dose consists of 120 mg extracts, wherein 118 mg is a water-soluble fraction, equivalent to 60 mg of alcohol extract, and 2 mg is a lipid soluble fraction.

Suitable excipients are the ones as normally used in the pharmaceutical industry such as a lactose preparation, starch, magnesium stearate, silicium dioxide. It may be possible to use other excipients and in other proportions.

The water-soluble extract is obtained by maceration, in water for 24-48 hours, the leaves and rhizomes of the ferns of *Polypodium aureum*, *Polypodium leucotomos*, *Polypodium vulgare*, *Polypodium trisereiale*, *Polypodium aquilinum*, *Drypteris crassirhizoma*, or *Cyathe taiwaniana*.  
5 The extract is characterized by the presence of quinine acid, malic acid, lactic acid, citric acid, fumaric acid and by the absence of any kind of sulfur lipid. The lipid soluble fraction is characterized by the presence of Neo-  
10 hop-13(18)-eno, Fern-9-(11)-eno, and Hop-(22)-29-eno as identified via mass spectrometry.

The documents of the prior art describe different activities, sometimes in an empirical manner without specifying  
15 the mechanism, of the polar and apolar extracts of the rhizomes and/or leaves of the ferns of the Polypodiaceae family.

The pharmacologically actions may be summarized as:

- 20 - Immuno-modulatory activity in diseases with a deficit in T-suppressor lymphocytes, infectious and autoimmunes, where the extracts exhibit an pleiotropic effect over the different populations of cytokines,
- 25 - Collagenpoyetic activity and application in psoriasis, atopic dermatitis,
- Anti-inflammatory activity of the osteolocomotor apparatus, principally the arthritis,
- Anti-inflammatory activity characterized by the  
30 inhibition of the plaque aggregation factor.

In none of the identified prior art documents it has been described that the extracts of the different ferns are capable of regulating the expression of the adhesion molecules nor that these are capable of regulating the lymphocyte CD4+CD29+CD45RA+ populations present in increased amounts in patients with multiple sclerosis.

#### **SUMMARY OF THE INVENTION**

The problem to be solved by the present invention is to provide a novel therapeutic application of the Anapsos 10 based on the regulation of the different cellular mediators. The regulation of the expression of the adhesion molecules (the decrease of the expression of the chains of integrins and the immunoglobulin superfamily) and the normalization of the lymphocyte CD4+CD29+CD45RA+ population makes the Anapsos a medicament suitable for treatment of diseases which relate to an inflammatory process, 15 in particular in the treatment of multiple sclerosis.

#### **DETAILED DESCRIPTION OF THE INVENTION:**

The present inventors have demonstrated, that the Anapsos 20 (118 mg of a water-soluble extract and 2 mg of a lipid soluble fraction of *Polypodium*) has regulatory effects in relation to the expression of adhesion molecules, in mononuclear cells of the peripheral blood of healthy humans, both in vivo and in vitro. Further, it has been demonstrated that Anapsos has a capacity similar to aza- 25 thioprine to recover the normality of the lymphocyte CD4+CD29+CD45RA+ population, present in increased amounts in patients with multiple sclerosis, thereby obtaining a stabilization of the patients.

At a dose from 0 to 5000 µg/ml of Anapsos and using different doses of phytohaemagglutinin, the Anapsos in vitro

is capable of inhibiting the increase of the expression of the adhesion molecules (CD54 and CD11b), as induced by the phytohaemagglutinin, in studies realized on mononuclear cells of human peripheral blood. The results are 5 most significant at a dose of 150 µg/ml of Anapsos and 10 µg/ml of phytohaemagglutinin.

After administration of 720 mg of extract per day for 11 days in a human, the Anapsos decreases the percentage of 10 the lymphocyte populations CD11a, CD11b, and CD54. Accordingly, the extract inhibits the expression of certain adhesion molecules of the integrins β2 (CD11a, CD11b) and of the superfamily of immunoglobulins (CD54).

15 Accordingly, beside the stimulating action on the cellular immunity as performed by the cytokines and its immuno-modulatory action as described in the art, the Anapsos has a strong anti-inflammatory capacity, similar to phenylbutazone, used as a control in anti-inflammatory 20 studies in rats. The anti-inflammatory effects of Anapsos has not been directly related to its capacity of regulating the expression of the adhesion molecules.

25 A pharmaceutical composition based on water-soluble and lipid soluble extracts of Polypodium has, in clinical studies performed on humans, been demonstrated to be effective against some diseases which involve inflammatory processes such as multiple sclerosis, prostatitis, and pharyngitis. Between them, these diseases have a different 30 aetiological cause.

Below, the invention is described by way of examples. These are not limiting on the scope of the invention.

**EXAMPLES:**

**Example 1. - Study of the anti-inflammatory capacity**

5 Materials:

Female WISTAR rats of 150 ±15g

Pletismometer LETICA

Weight METTLER AJ 100

Weight COBOS D 600

10 Phenylbutazone

DIFCO

CMC and Tween 80

Method:

A study of the anti-inflammatory activity has been made

15 in acute and chronic phase in rats. The method used was

as described by Mizushima. The reference medicament

(Phenylbutazone, dose 80 mg/Kg) and the products of the

study (dose equivalent to 1.25 g extract per kg weight of

animal) were dissolved in a solution of 1% of CMC (car-

20 boxymethylcellulose) in distillated water (w/v) and Tween

80: distillated water (0.2:3.3 -v/v), in order to be ad-

ministrated orally.

Six days after inoculation, by intradermal route of 0.1

25 mL of the complete adjuvant Freund (DIFCO) in the basal

part of the tail, was injected 0.1 mL of a suspension of

carrageenin type IV 2% (w/v) at the aponeurosis of the

left back foot.

The volume of the foot of the animal was measured, using a water plethysmometer, immediately before the carrageenin injection (basal volume) and afterwards at 3, 5, and 7 hours (acute phase of the inflammation) and at 24, 48, 5 72, and 96 hours (chronic phase of inflammation).

The products of the study, the phenylbutazone, and the carrier were administrated, orally and in portions of 6 animals, 1 hour before the carrageenin injection and at 10 24, 48 and 72 hours.

#### Results:

The percentage of inhibition of the inflammation was calculated by comparing the increase of the volume of the 15 animal foot in respect of its basal volume, for each group of animals and in relation to the control group. The control group was given the carrier of phenylbutazone and the products of the study. The statistical significance was evaluated via the T Student test. The results 20 are shown below.

% INHIBITION OF THE INFLAMMATION							
	3 h	5 h	7 h	24 h	48 h	72 h	96 h
Control	---	---	---	---	---	---	---
Phenylbutazone	41%	27%	21%	36%	60%	56%	40%
Anapsos	29%	35%	41%	43%	50%	54%	48%

The results show that the Polypodium extract exhibits an inhibitory activity on the inflammation, superior to the control in the acute phase and similar to phenylbutazone 25 in the acute phase.

**Example 2. - Clinical studies of the effect of Anapsos against different pathologies:**

Multiple sclerosis: Patients with multiple sclerosis were over 1 year provided with a treatment of 720 mg extract/day. The result was that the for the disease most characteristic alterations of the immunological phenotype were corrected giving a clinical stabilization of the patients. Further, the lymphocyte CD4+CD29+CD45RA+ population was normalized.

10

Prostatitis: Three days treatment with a dose of 240 mg extract, 60 minutes before the principal dinners, gave an improvement of the patients and all symptoms disappeared.

15 Pharyngitis: A dose of 120 mg extract gave favorable effects in the problems of pharyngitis, in particular for pharyngitis in its subacute period.

**Example 3. - In vitro study of the adhesion molecules in Peripheral Blood Mono-Nuclear cells (PBMNc).**

Peripheral blood was extracted from 10 healthy individuals and the mononuclear cells was separated via Fycoll-Hypaque density gradient centrifugation. The cells was cultivated in plane bottom microtiter plates, at a titer of 1 million/ml for 48 hours in a CO<sub>2</sub> incubator, with phytohaemagglutinin (PHA) at concentrations of 0, 0.5, 2, 5 and 10 µg/ml and/or with Anapsos at concentrations between 0 to 5000 µg/ml.

30 Finalized the culturing, the lymphocytes was analyzed by flow cytometry. The expression of determined adhesion

molecules (CD11a, CD11b, CD18, CD54) was studied in relation to the different conditions of stimuli. En parallel to the culture as described above, a culture for 5 days was made under the same conditions of stimuli as above. 5 Tritium thymidine was added 16 hours before finalizing the culture. Terminated the culture, the cells was washed with the Harvester and flashing liquid was incorporated into the cells. The cellular incorporation of tritium thymidine was measured via a  $\beta$  counter. During the culturing, the cells were photographed via an inverted microscope. The results are shown below.

Expression, in vitro, of different adhesion molecules of peripheral blood mononuclear cells.

15

N= 10	CD11a	CD11b	CD18	CD54
PHA10	22%	35%	27%	9%
ANP 150	15%	14%	19%	0%
PHA+ANP	16%	23%	25%	3%
CONTROL	17%	20%	20%	2%

20 **Example 4. - Expression in vivo of the adhesion molecules in Peripheral Blood Mono-Nuclear cells (PBMNC).**

10 voluntary persons took for 11 consecutive days 720 mg/day of Anapsos. Peripheral blood was extracted from all of those persons the day before starting the treatment, the day after, at four days, and after the final 25 administration. The mononuclear cells was separated via Fycoll-Hypaque density gradient centrifugation and the different lymphocyte populations were analyzed with respect of the differentiation markers CD11a and CD11b. The 30 results are shown below.

## Expression, in vitro, of different adhesion molecules of peripheral blood mononuclear cells.

	N= 10	PRE	24H	72H	96H	RETIRED
5	CD11b	13%	4%	2%	1%	12%
	CD11a	14%	6%	3%	1%	15%

## C L A I M S

1. Use of the Anapsos, a natural extract isolated from the rhizomes of *Polypodium*, comprising a water-soluble fraction, a lipid soluble fraction and a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical medicament for regulation of the expression of adhesion molecules.  
5
- 10 2. The use of claim 1, wherein the regulation of the expression of adhesion molecules is characterized by a reduction of the expression of the alpha chains of the integrin  $\beta$ -2 and/or the beta chain of the integrin  $\beta$ -2.
- 15 3. The use of claim 1, wherein the regulation of the expression of adhesion molecules is characterized by a reduction of the expression of the CD54.
- 20 4. The use of claim 1, wherein the regulation of the expression of adhesion molecules is characterized by a decrease in the amount of the differentiation antigens CD11b and/or CD6L.
- 25 5. The use of claim 1, wherein the medicament is used as an anti-inflammatory and/or immuno-modulatory agent and the medicament is characterized by its capacity for regulation of the expression of adhesion molecules.
- 30 6. Use of the Anapsos, a natural extract isolated from the rhizomes of *Polypodium*, comprising a water-soluble fraction, a lipid soluble fraction and a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical medicament for normalizing the lymphocyte

CD4+CD29+CD45RA+ populations in pathologies where said populations are increased.

7. The use of claim 6, for the treatment of multiple  
5 sclerosis.

A B S T R A C T

Pharmaceutical composition with adhesion molecule expression regulating activity.

5

The invention relates to a novel pharmaceutical application of a pharmaceutical composition exhibiting regulating activity of the expression of adhesion molecules integrins, selectins and immunoglobulins and its application as anti-inflammatory agent. Said pharmaceutical composition contains Anapsos, a water-soluble extract and a lipo-soluble extract of the rhizomes of Polypodium leucotomos as active substance in addition to acceptable excipients.

10

# DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name: that I verily believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought in the application entitled:

## "Pharmaceutical composition with adhesion molecule expression regulating activity"

which application is:

, filed

the attached application  
(for original application)

application Serial No. 09/889,846  
filed on July 23, 2001

(for Declaration not accompanying application)

that I have reviewed and understand the contents of the specification of the above-identified application, including the claims, as amended by any amendment referred to above; that I acknowledge my duty to disclose information of which I am aware which is material to the patentability of this application under 37 C.F.R. 1.56., that I hereby claim priority benefits under Title 35, United States Code §119, §172 or §365 of any provisional application or foreign application(s) for patent or inventor's certificate listed below and have also identified on said list any foreign application for patent or inventor's certificate of this invention having a filing date before that of any foreign application on which priority is claimed:

Application Number	Country	Filing Date	Priority Claimed (yes or no)
P 9900182	SPAIN	January 25, 1999	YES

I hereby claim the benefit of Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose any information material to the patentability of this application under 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (patented, pending, abandoned)
PCT/ES00/00026	January 25, 2000	Published

I hereby appoint John H Mion, Reg. No. 18,879; Thomas J. Macpeack, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Wadell A. Biggart, Reg. 24861; Louis Gubinsky, Reg. No. 24,835; Neil B Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. 32,197; William H. Mandir, Reg. No. 32,156; Scott M. Daniels, Reg. No. 32,562; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765, and Robert M. Masters, Reg. No. 35,603 my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office therewith, and request that all correspondence about the application be addressed to SUGHRUE, MION, ZINN, MACPEACK & SEAS PLLC, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3202.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date March 8, 2002 100  
First inventor Eliseo Quintanilla Almagro  
First Name Middle Initial Last Name  
Signature \_\_\_\_\_  
Residence 03006 ALI Spain ESX Post Office Address 14, calle Sagitario  
Citizenship Spain

Date March 8, 2002 200  
Second inventor Joaquín Sr. Diaz DIAZ ALPERI  
First Name Middle Initial Last Name  
Signature \_\_\_\_\_  
Residence 03006 ALI Spain ESX Post Office Address 14, calle Sagitario  
Citizenship Spain

Applicant or Patentee: Eliseo QUINTANILLA ALMAGRO and Joaquín DIAZ ALPERI Attorney's Docket  
Application No. S.N. 09/889846 No. Q-65077  
Filed or Issued: July 23, 2001  
For: PHARMACEUTICAL COMPOSITION WITH ADHESION MOLECULE  
EXPRESSION REGULATING ACTIVITY

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27 (c)) – SMALL BUSINESS CONCERN**

I hereby declare that I am

- the owner of the small business concern identified below:  
 an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN ESPECIALIDADES FARMACEUTICAS CENTRUM, S.A.

ADDRESS OF CONCERN 14, calle Sagitario, 03006 ALICANTE, Spain

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41 (a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third or parties controls or has the power to control both.

I hereby declare that rights under contact or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled: **PHARMACEUTICAL COMPOSITION WITH ADHESION MOLECULE EXPRESSION REGULATING ACTIVITY** by inventors **Eliseo QUINTANILLA ALMAGRO and Joaquín DIAZ ALPERI**.

Described in

- the specification filed herewith  
 application no. S.N. 09/889846 filed July 23, 2001  
 patent no. \_\_\_\_\_ issued \_\_\_\_\_

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statement are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

FULL NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_

INDIVIDUAL

SMALL BUSINESS CONCERN

NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON

SIGNING

ELISEO QUINTANILLA ALMAGRO

General Director


TITLE IN ORGANIZATION

ADDRESS OF PERSON

SIGNING

14, Calle Sagitario, 03006 ALICANTE, Spain

Signature



Date February 14, 2002

O/ ESPECIALISTAS FARMACEUTICAS CENTRUM, S.A

ALICANTE

